Merck Advances Terns Deal And Cardiovascular And RSV Growth Options [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck (NYSE:MRK) reported the expiration of the Hart Scott Rodino waiting period for its pending acquisition of Terns Pharmaceuticals, clearing a key US regulatory hurdle. The Terns deal is intended to expand Merck's presence in autoimmune and metabolic diseases. Merck announced CADENCE trial proof of concept data for Winrevair in heart failure with preserved ejection fraction. The European Commission approved ENFLONSIA for RSV prevention in infants. For investors following Merck, these updates highlight how the business is trying to build out its portfolio beyond oncology, particularly into cardiovascular, autoimmune, metabolic and infectious disease prevention. Heart failure with preserved ejection fraction and RSV in infants both aim at areas of high clinical need, which helps explain why these programs sit alongside the Terns acquisition as priorities for NYSE:MRK. Looking ahead, attention is likely to focus on how quickly Merck can integrate Terns' programs and advance
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck: Bullish Setup Into Q1 Earnings [Seeking Alpha]Seeking Alpha
- Sun Pharma to acquire Organon in $11.75 billion deal [Yahoo! Finance]Yahoo! Finance
- Sun Pharma to acquire Organon for $11.75bn [Yahoo! Finance]Yahoo! Finance
- Merck & Co. Inc. (MRK): One of the Best Low Risk High Growth Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Summers Value Partners Q4 2025 Partner Letter [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website